What's Going On With Sonnet BioTherapeutics Stock Today?

Sonnet BioTherapeutics Holdings Inc SONN shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 (IL12-FHAB) in combination with Roche Holding AG's RHHBY atezolizumab, has been accepted, and the study can begin in the U.S. for platinum-resistant ovarian cancer (PROC)

The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (MTD) of SON-1010 with a fixed dose of atezolizumab. 

Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (RP2D). 

Part 2 of the study will then investigate SON-1010 monotherapy, its use in combination with atezolizumab, or the standard of care (SOC) for PROC in a randomized comparison to show proof-of-concept.

SB221 is a global Phase 1b/2a multicenter, dose-escalation and randomized POC study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). 

Price Action: SONN shares are up 23.78% at $0.40 at publication Wednesday.

Read Next: Why Performance Food Shares Are Gaining Today

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!